- Home
- GNPX vs AMBO Comparison
GNPX vs AMBO Comparison
Compare GNPX & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- AMBO
- Stock Information
- Founded
- GNPX 2009
- AMBO 2000
- Country
- GNPX United States
- AMBO United States
- Employees
- GNPX N/A
- AMBO N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- AMBO Other Consumer Services
- Sector
- GNPX Health Care
- AMBO Real Estate
- Exchange
- GNPX Nasdaq
- AMBO Nasdaq
- Market Cap
- GNPX 6.1M
- AMBO 6.0M
- IPO Year
- GNPX 2018
- AMBO 2010
- Fundamental
- Price
- GNPX $0.75
- AMBO $2.06
- Analyst Decision
- GNPX Strong Buy
- AMBO
- Analyst Count
- GNPX 1
- AMBO 0
- Target Price
- GNPX $10.00
- AMBO N/A
- AVG Volume (30 Days)
- GNPX 367.1K
- AMBO 528.7K
- Earning Date
- GNPX 11-13-2024
- AMBO 12-30-2024
- Dividend Yield
- GNPX N/A
- AMBO N/A
- EPS Growth
- GNPX N/A
- AMBO N/A
- EPS
- GNPX N/A
- AMBO N/A
- Revenue
- GNPX N/A
- AMBO $7,839,000.00
- Revenue This Year
- GNPX N/A
- AMBO N/A
- Revenue Next Year
- GNPX N/A
- AMBO N/A
- P/E Ratio
- GNPX N/A
- AMBO N/A
- Revenue Growth
- GNPX N/A
- AMBO N/A
- 52 Week Low
- GNPX $0.28
- AMBO $1.00
- 52 Week High
- GNPX $13.00
- AMBO $6.30
- Technical
- Relative Strength Index (RSI)
- GNPX 40.74
- AMBO 49.76
- Support Level
- GNPX $0.66
- AMBO $1.77
- Resistance Level
- GNPX $0.74
- AMBO $2.29
- Average True Range (ATR)
- GNPX 0.06
- AMBO 0.48
- MACD
- GNPX 0.00
- AMBO -0.06
- Stochastic Oscillator
- GNPX 35.04
- AMBO 25.47
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.